PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022There are no long-term effective therapies for Ps...
portfolios and create effective counter-strategies to gain a competitive advantage.table Of Contents1table Of Contents11.1...
5.2.3japan265.2.4china265.2.5india285.3forecast Methodology295.3.1sources Used295.3.2forecast Assumptions And Methods335.3...
6.9.2clinical Practice666.10india 686.10.1diagnosis686.10.2clinical Practice687competitive Assessment697.1overview697.2str...
9.4promising Drugs In Clinical Development1159.4.1brodalumab (amg 827)1179.4.2secukinumab (ain457)1239.4.3ixekizumab (ly24...
11.4.3drivers And Barriers20411.5italy 20611.5.1forecast20611.5.2key Events20911.5.3drivers And Barriers21011.6spain 21111...
12.7.1analysts26112.7.2epidemiologist26212.7.3reviewers26312.7.4global Director Of Epidemiology And Clinical Trials Analys...
Upcoming SlideShare
Loading in...5
×

PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

145

Published on

There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

Annualized market revenues data for 9 key markets
Annualized market revenues data from 2012 to 2022 and forecast from 2012 to 2022
Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by the 9 key markets. Pipeline candidates fall under major therapeutic classes.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
145
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022"

  1. 1. PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmetneeds. While physicians agree that biologics are relatively safe and effective, these therapies are still lackingbecause of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.ScopeAnnualized market revenues data for 9 key markets Annualized market revenues data from 2012 to 2022 andforecast from 2012 to 2022 Pipeline analysis data providing a split across the different phases, mechanisms ofaction being developed and emerging trends by the 9 key markets. Pipeline candidates fall under majortherapeutic classes. Analysis of key recent licensing and partnership agreements in the PsO Therapeuticsmarket. Insightful review of the key industry drivers, restraints and challenges. Each trend is independentlyresearched to provide a qualitative analysis of its implications. Key topics covered include strategic competitorassessment, market characterization, unmet needs and implicationsMarket Model FeaturesAn interactive excel forecast model based on primary research interviews and surveys with KOLs andhigh-prescribing physicians is included in this report*. This patient based model provides diagnosis rates,patient segmentation, treatment rates, annual costs of therapy , and indication-specific drug sales for the 10year forecast period. The forecast model is robust, fully transparent, and easy to navigate. Moreover, ourmodels support data presented in the reports and the complete methodology is outlined in the report and themodel.*Model only available with site and global license purchases.Key FindingsThe global PsO therapeutics market is forecast to reach $7.61 billion by 2022 due to the launch of novelpipeline drugs and biosimilars. All the leading branded biologics: Humira, Remicade, Stelara, and Enbrel, willface the emergence of biosimilars as well as novel oral and injectable pipeline drugs. By 2022, PsO will be acrowded marketplace comprising a highly diversified field of therapies with individual drugs struggling todistinguish themselves.Key Questions Answered in this ReportHow will the patent expiry of Enbrel, Humira , Remicade, and Stelara affect the competitive landscape?When will biosimilars emerge and how will they affect the market? What effect have changing regulations hadon companies investing in the sector? Who is the frontrunner in the drug pipeline for PsO and what are itsstrengths and weaknesses? Will pipeline drugs be able to compete with the TNF inhibitors? Where arecompanies investing R&D in 2013?Key BenefitsDevelop and design your in-licensing and out-licensing strategies through a review of pipeline products andtechnologies and by identifying the companies with the most robust pipeline. Develop business strategies byunderstanding the trends shaping and driving the global market. Drive revenues by understanding the keytrends, innovative products and technologies, market segments and companies likely to impact the market infuture. Formulate effective sales and marketing strategies by understanding the competitive landscape and byanalyzing the performance of various competitors. Identify emerging players with potentially strong productPharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022
  2. 2. portfolios and create effective counter-strategies to gain a competitive advantage.table Of Contents1table Of Contents11.1list Of Tables51.2list Of Figures72executive Summary82.1sales For Psoriasis By Region 2012–202292.2research And Development And Corporate Strategies102.3unmet Needs In Psoriasis112.4new Entrant Opportunities112.5pipeline Agents And Future Landscape112.6what Do The Physicians Think?133introduction143.1catalyst143.2related Reports143.3upcoming Related Reports144disease Overview144.1etiology And Pathophysiology144.1.1etiology144.1.2pathophysiology164.2symptoms195epidemiology195.1risk Factors And Comorbidities195.1.1family History Of Psoriasis Increases The Risk Of Developing The Disease By Nearly 20 Times215.1.2obesity Doubles The Risk Of Psoriasis215.1.3smoking, Combined With Other Risk Factors, Increases The Risk For Psoriasis Up To Nine Times215.1.4psoriatic Arthritis Is Present In Up To 40.0% Of All Psoriasis Patients235.1.5nearly Half Of All Psoriasis Patients Report Elevated Stress Levels, Depression, And Thoughts OfSuicide245.2global And Historical Trends255.2.1us255.2.25eu26PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022
  3. 3. 5.2.3japan265.2.4china265.2.5india285.3forecast Methodology295.3.1sources Used295.3.2forecast Assumptions And Methods335.3.3sources Not Used375.4epidemiology Forecast (2012–2022)385.4.1prevalent Cases Of Psoriasis385.4.2age-specific Prevalent Cases Of Psoriasis405.4.3sex-specific Prevalent Cases Of Psoriasis425.4.4age-standardized Prevalence Of Psoriasis445.5discussion455.5.1conclusions On Epidemiology Trends455.5.2limitations Of The Analysis455.5.3strengths Of The Analysis476disease Management476.1treatment Overview486.2us 516.2.1diagnosis516.2.2clinical Practice526.3france546.3.1diagnosis546.3.2clinical Practice546.4germany566.4.1diagnosis566.4.2clinical Practice576.5italy 586.5.1diagnosis586.5.2clinical Practice586.6spain 606.6.1diagnosis606.6.2clinical Practice606.7uk 626.7.1diagnosis626.7.2clinical Practice626.8japan646.8.1diagnosis646.8.2clinical Practice646.9china666.9.1diagnosis66PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022
  4. 4. 6.9.2clinical Practice666.10india 686.10.1diagnosis686.10.2clinical Practice687competitive Assessment697.1overview697.2strategic Competitor Assessment707.3product Profiles – Major Brands717.3.1enbrel (etanercept)717.3.2humira (adalimumab)787.3.3remicade (infliximab)837.3.4stelara (ustekinumab)897.3.5taclonex (calcipotriene Hydrate And Betamethasone Dipropionate)947.3.6methotrexate Sodium (numerous Generic Names)997.3.7minor Therapeutic Drug Classes Used In Psoriasis1037.3.8non-pharmacological Therapy1048opportunity And Unmet Need1058.1overview1058.2unmet Needs1078.2.1improved Drug Safety And Efficacy Profiles1078.2.2biomarkers For Predicting Remission1078.2.3more Cost-effective Therapies Through Oral Formulation And Biosimilars1088.2.4education And Treatment Of Psychological Factors Accompanying Psoriasis1088.2.5an Effective Biologic/systemic Topical Therapy1098.2.6more Effective Treatment For Mild Psoriasis, Specifically Uv Therapies1098.2.7physician Education About The Different Types Of Psoriasis, Not Just Plaque Psoriasis1098.3opportunities1108.4unmet Needs Gap Analysis1108.4.1predictive Tools For Diagnosis And Treatment1118.4.2target Specificity1118.4.3topical Biologic/systemic Therapeutic Options1118.4.4helping Patients With Psychological Issues Associated With Psoriasis1129pipeline Assessment1129.1overview1129.2clinical Trial Mapping1139.2.1clinical Trials By Country1139.3clinical Trials By Phase And Trial Status114PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022
  5. 5. 9.4promising Drugs In Clinical Development1159.4.1brodalumab (amg 827)1179.4.2secukinumab (ain457)1239.4.3ixekizumab (ly2439821)1279.4.4tildrakizumab (mk-3222/sch-900222)1339.4.5xeljanz (tofacitinib)1389.4.6apremilast (cc-10004)1449.4.7alzumab (itolizumab)1509.4.8phase Ii Pipeline Products1549.4.9phase I Pipeline Products1559.4.10biosimilars Pipeline Products15610current And Future Players15810.1overview15810.2trends In Corporate Strategy16110.3company Profiles16310.3.1amgen16310.3.2abbvie (abbott)16510.3.3johnson & Johnson16710.3.4novartis16910.3.5pfizer17110.3.6eli Lilly17310.3.7merck17510.3.8leo Pharma17710.3.9celgene17911market Outlook18011.1global Markets18011.1.1forecast18011.1.2drivers And Barriers – Global Issues18611.2united States19011.2.1forecast19011.2.2key Events19311.2.3drivers And Barriers19311.3france19611.3.1forecast19611.3.2key Events19911.3.3drivers And Barriers19911.4germany20111.4.1forecast20111.4.2key Events204PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022
  6. 6. 11.4.3drivers And Barriers20411.5italy 20611.5.1forecast20611.5.2key Events20911.5.3drivers And Barriers21011.6spain 21111.6.1forecast21111.6.2key Events21411.6.3drivers And Barriers21411.7united Kingdom21511.7.1forecast21511.7.2key Events21811.7.3drivers And Barriers21811.8japan22111.8.1forecast22111.8.2key Events22411.8.3drivers And Barriers22411.9china22711.9.1forecast22711.9.2key Events22911.9.3drivers And Barriers22911.10india23111.10.1forecast23111.10.2key Events23311.10.3drivers And Barriers23312appendix23412.1bibliography23412.2abbreviations24812.3methodology25012.4forecasting Methodology25012.4.1diagnosed Psoriasis Patients25012.4.2percent Drug-treated Patients25112.4.3drugs Included In Each Therapeutic Class25112.4.4launch And Patent Expiry Dates25212.4.5general Pricing Assumptions25312.4.6individual Drug Assumptions25412.4.7generic Erosion25612.4.8pricing Of Pipeline Agents25812.5physicians And Specialists Included In This Study25912.6primary Research – Prescriber Survey26012.7about The Authors261PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022
  7. 7. 12.7.1analysts26112.7.2epidemiologist26212.7.3reviewers26312.7.4global Director Of Epidemiology And Clinical Trials Analysis26412.7.5global Head Of Healthcare26412.8about Globaldata26512.9contact Us26512.10disclaimer265ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market researchreports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with ourhuge collection of market research reports. We provide our services to all sizes of organizations and across allindustry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well aspublishers and will assist you in making an informed decision by giving you unbiased and deep insights onwhich reports will satisfy your needs at the best price.Contact:M/s Sheela,90 State Street,Suite 700,Albany NY - 12207United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usWebsite: http://www.researchmoz.us/PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022

×